December 19, 2019
December 19, 2019 - Somerset, NJ - As part of its ongoing commitment of Contributing to Society through Healthcare, Terumo Medical Corporation (TMC) has recently launched a newly established, organization-wide Women's Initiative Network (WIN).
The mission of WIN is to drive gender diversity throughout the the company, as a means to spur sustainable business growth, encourage a culture of respect and inclusion, and support initiatives aimed at women's professional growth and leadership.
WIN will focus on four (4) strategic pillars:
1. Develop the company's corporate culture further to drive a collaborative, connected and inclusive organization.
2. Introduce a developmental program, which will support active learning and professional growth for TMC Associates.
3. Advocate for internal policy change, driven by focus groups.
4. Enhance organizational integration, where TMC will partner with outside organizations and industry partners to support additional women's initiatives.
While the conversations and topics focus on women in the workforce, WIN believes the events and networks offered are valuable for both women and men of Terumo as we drive a culture of inclusion, diversity and belonging.
TMC is now a proud member of Catalyst, a global nonprofit founded in 1962 that works with many of the world's most powerful CEOs and leading companies to help build workplaces that work for women and other underrepresented groups.
"As TMC expands and grows, it has been my mission to turn our innovative forces inward to develop Associates to their highest potential - so they can achieve their professional aspirations. This enables TMC to build a culture of understanding, embrace differences in style and consider alternative profiles for success. Thriving WIN programs embrace and promote the principles of inclusion for all people. At TMC, we are guided by our Terumo Core Values, which include respect and appreciation towards all Associates and embracing initiatives such as WIN," said Jim Rushworth, President & CEO, Terumo Medical Corporation.
Terumo Medical Corporation (TMC) is a subsidiary of Terumo Corporation, founded in 1972 as the United States expansion of our larger Tokyo-based parent. For nearly 50 years, we've continued the Terumo mission of offering the best possible solutions to healthcare providers and the people they serve.
Backed by Terumo Corporation's almost 100 years of experience, TMC has grown from offering a small range of products to manufacturing huge product lines across four divisions: Terumo Interventional Systems (TIS), which offers solutions for entry site management and lesion access; Terumo Medical Products (TMP), which provides devices for injection and infusion therapy; Terumo Pharmaceutical Solutions (TPS), which develops drug delivery devices; and Terumo Business Edge, which offers cardiac cath lab consulting. It's all part of our continued commitment to the values of our founders and "Contributing to Society Through Healthcare." To learn more visit, www.terumomedical.com.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with approximately US$6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.